Literature DB >> 34141084

SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression.

Haibin Zhou1, Longchuan Bai1, Renqi Xu1, Donna McEachern1, Krishnapriya Chinnaswamy1, Ruiting Li1, Bo Wen1, Mi Wang1, Chao-Yie Yang1, Jennifer L Meagher1, Duxin Sun1, Jeanne A Stuckey1, Shaomeng Wang1.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is an attractive cancer therapeutic target. We report herein our extensive in vitro and in vivo evaluations of SD-91, the product of the hydrolysis of our previously reported STAT3 degrader SD-36. SD-91 binds to STAT3 protein with a high affinity and displays >300-fold selectivity over other STAT family protein members. SD-91 potently and effectively induces degradation of STAT3 protein and displays a high selectivity over other STAT members and >7000 non-STAT proteins in cells. A single administration of SD-91 selectively depletes STAT3 protein in tumor tissues with a persistent effect. SD-91 achieves complete and long-lasting tumor regression in the MOLM-16 xenograft model in mice even with weekly administration. Hence, SD-91 is a potent, highly selective, and efficacious STAT3 degrader for extensive evaluations for the treatment of human cancers and other diseases for which STAT3 plays a key role.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 34141084      PMCID: PMC8201759          DOI: 10.1021/acsmedchemlett.1c00155

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  13 in total

Review 1.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

2.  Light-switched inhibitors of protein tyrosine phosphatase PTP1B based on phosphonocarbonyl phenylalanine as photoactive phosphotyrosine mimetic.

Authors:  Stefan Wagner; Anja Schütz; Jörg Rademann
Journal:  Bioorg Med Chem       Date:  2015-04-04       Impact factor: 3.641

Review 3.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

4.  Benzoylphosphonate-based photoactive phosphopeptide mimetics for modulation of protein tyrosine phosphatases and highly specific labeling of SH2 domains.

Authors:  André Horatscheck; Stefan Wagner; Jutta Ortwein; Boo Geun Kim; Michael Lisurek; Samuel Beligny; Anja Schütz; Jörg Rademann
Journal:  Angew Chem Int Ed Engl       Date:  2012-08-21       Impact factor: 15.336

Review 5.  Multispecific drugs herald a new era of biopharmaceutical innovation.

Authors:  Raymond J Deshaies
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

Review 6.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

7.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Authors:  Longchuan Bai; Haibin Zhou; Renqi Xu; Yujun Zhao; Krishnapriya Chinnaswamy; Donna McEachern; Jianyong Chen; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Hui Jiang; Bo Wen; Praveen Kumar; Jennifer L Meagher; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  Cancer Cell       Date:  2019-11-11       Impact factor: 31.743

Review 8.  Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?

Authors:  Jenny D Beebe; Jing-Yuan Liu; Jian-Ting Zhang
Journal:  Pharmacol Ther       Date:  2018-06-20       Impact factor: 12.310

9.  Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

Authors:  Haibin Zhou; Longchuan Bai; Renqi Xu; Yujun Zhao; Jianyong Chen; Donna McEachern; Krishnapriya Chinnaswamy; Bo Wen; Lipeng Dai; Praveen Kumar; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Jennifer L Meagher; Han Yi; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2019-12-10       Impact factor: 7.446

Review 10.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24
View more
  1 in total

Review 1.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.